Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL22980338

Cc1c(F)cccc1S(=O)(=O)Nc1c(F)cc(C#Cc2cncc(F)c2)cc1F.O=C(O)C(F)(F)F

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 1/20 0.39
BRPF1 P55201 1/20 0.36
KAT6A Q92794 2/20 0.35
SLC22A12 Q96S37 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
EGLN3 Q9H6Z9 1/20 0.35
KDR P35968 2/20 0.35
NR3C2 P08235 1/20 0.34
PDGFRB P09619 1/20 0.34
HDAC4 P56524 3/20 0.33
PIK3CA P42336 2/20 0.33
PIK3C3 Q8NEB9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29434888 0.92 SLC40A1 (0.44) SLC40A1BRPF1KAT6ASLC22A12KDR
SCHEMBL22980265 0.92 SLC40A1 (0.44) SLC40A1BRPF1KAT6ASLC22A12KDR
Trifluoroacetic Acid SCHEMBL28718812 0.85 HSD11B1 (0.39) SLC40A1
Trifluoroacetic Acid SCHEMBL28718803 0.85 HSD11B1 (0.39) SLC40A1SLC22A12KDRNR3C2PDGFRB
Trifluoroacetic Acid SCHEMBL22980528 0.84 ACLY (0.34) EGLN1EGLN3PIK3CAPIK3C3
SCHEMBL22980440 0.84 HSD11B1 (0.45) SLC40A1
SCHEMBL29434864 0.84 HSD11B1 (0.45) SLC40A1
Trifluoroacetic Acid SCHEMBL22980521 0.81 PIK3CA (0.37) KAT6AEGLN1EGLN3KDRNR3C2
Trifluoroacetic Acid SCHEMBL29666103 0.81 PIK3CA (0.37) KAT6AEGLN1EGLN3KDRNR3C2
SCHEMBL22980356 0.79 PTGES2 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114174266-A Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators 豪夫迈·罗氏有限公司 2022-03-11 CN claimed
EP-4013495-B1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS HOFFMANN LA ROCHE (CH) 2023-09-27 EP disclosed
EP-4013495-A1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS F. Hoffmann-La Roche AG (CH) 2022-06-22 EP disclosed
US-20220169599-A1 ARYLSULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2022-06-02 US disclosed
CN-114174266-A Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators 豪夫迈·罗氏有限公司 2022-03-11 CN disclosed
WO-2021028512-A1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169599-A1 ARYLSULFONAMIDE DERIVATIVES ARSA, SULT1E1, STS SLC40A1 3174/4885BRPF1 2674/4885KAT6A 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.